| Identification | Back Directory | [Name]
N-[(1R)-1-[[[[4-[[(Aminocarbonyl)amino]methyl]phenyl]methyl]amino]carbonyl]-4-[(aminoiminomethyl)amino]butyl]-α-phenyl-benzeneacetamideditrifluoroacetate | [CAS]
191868-14-1 | [Synonyms]
BIBO 3304
BIBO3304 TFA
BIBO 3304
(BIBO3304)
BIBO 3304 trifluoroacetate
N-[(1R)-1-[[[[4-[[(Aminocarbonyl)amino]methyl]phenyl]methyl]amino]carbonyl]-4-[(aminoiminomethyl)amino]butyl]-α-phenyl-benzeneacetamideditrifluoroacetate | [Molecular Formula]
C31H36F3N7O5 | [MOL File]
191868-14-1.mol | [Molecular Weight]
643.67 |
| Chemical Properties | Back Directory | [storage temp. ]
Store at +4°C | [solubility ]
<75.77mg/ml in DMSO; <75.77mg/ml in ethanol | [form ]
solid | [color ]
White | [InChIKey]
FBMCYYWIBYEOST-NETKZVBLNA-N | [SMILES]
C(F)(F)(F)C(=O)O.C(C1C=CC=CC=1)(C1C=CC=CC=1)C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC1C=CC(CNC(=O)N)=CC=1 |&1:23,r| |
| Hazard Information | Back Directory | [Uses]
BIBO 3304 Trifluoroacetate is a high affinity NPY1-R antagonist, that inhibits NPY- and fasting-induced feeding in vivo following central administration. blockade of Y1 receptors may offer a novel anabolic treatment option for improving bone mass. | [in vivo]
BIBO3304 (30 μg; bilateral paraventricular nucleus injection) attenuates the hyperphagia following fasting[1].
BIBO3304 (15-60 μg) dose-dependently inhibits the feeding reponse mediated by 1 μg NPY[1].
BIBO3304 (0.5?μM; p.o.) significantly increases serum insulin levels[2]. | Animal Model: | Adult male Chbb:Thom rats weighing between 300 and 340 g[1] | | Dosage: | 30 μg | | Administration: | bilateral paraventricular nucleus injection | | Result: | Attenuated the hyperphagia following fasting, especially during the first 2 h of refeeding.
|
| Animal Model: | 7-week-old C57BL/6JAusb mice[2] | | Dosage: | 0.5?μM | | Administration: | p.o. | | Result: | Significantly increased serum insulin levels.
|
| [IC 50]
NPY Y1 receptor | [storage]
Store at -20°C |
|
|